Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Net Income (2016 - 2025)

Historic Net Income for Iovance Biotherapeutics (IOVA) over the last 12 years, with Q3 2025 value amounting to -$91.3 million.

  • Iovance Biotherapeutics' Net Income fell 923.14% to -$91.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$397.7 million, marking a year-over-year increase of 299.44%. This contributed to the annual value of -$372.2 million for FY2024, which is 1617.94% up from last year.
  • As of Q3 2025, Iovance Biotherapeutics' Net Income stood at -$91.3 million, which was down 923.14% from -$111.7 million recorded in Q2 2025.
  • Iovance Biotherapeutics' 5-year Net Income high stood at -$78.6 million for Q4 2024, and its period low was -$116.4 million during Q4 2023.
  • Over the past 3 years, Iovance Biotherapeutics' median Net Income value was -$107.4 million (recorded in 2023), while the average stood at -$103.2 million.
  • Its Net Income has fluctuated over the past 5 years, first skyrocketed by 3247.31% in 2024, then plummeted by 1505.37% in 2025.
  • Over the past 3 years, Iovance Biotherapeutics' Net Income (Quarter) stood at -$116.4 million in 2023, then soared by 32.47% to -$78.6 million in 2024, then decreased by 16.14% to -$91.3 million in 2025.
  • Its Net Income stands at -$91.3 million for Q3 2025, versus -$111.7 million for Q2 2025 and -$116.2 million for Q1 2025.